1887
Volume 2025, Issue 2
  • ISSN: 0253-8253
  • E-ISSN: 2227-0426

Papillary thyroid carcinoma (PTC) accounts for 90% of thyroid malignancies, with lymph node metastasis being a critical prognostic factor. However, the mechanisms driving metastasis remain unclear. This study investigated the role of E-cadherin and zinc finger E-box-binding homeobox 1 in cancer progression among Iraqi PTC patients.

The expression levels of E-cadherin and zinc finger E-box-binding homeobox 1 were analyzed in 50 Iraqi patients diagnosed with PTC without lymph node metastases, evaluated between January 2015 and December 2021. The Pearson correlation coefficient between these markers and the risk of lymph node metastasis, as well as their relationship to tumor grade and stage, was calculated. The area under the receiver operating characteristic (ROC) curve for both markers was performed. The Medical Ethics Committee of the Iraqi Ministry of Higher Education and Scientific Research (Reference No. 14) approved the study.

This study examined 50 PTC cases, revealing significant associations between E-cadherin and zinc finger E-box-binding homeobox 1 expression and lymph node metastasis, clinical stage, and tumor grade. Zinc finger E-box-binding homeobox 1 expression was higher in metastatic cases (92% vs. 16%), while E-cadherin was lower (24% vs. 84%). Zinc finger E-box-binding homeobox 1 positively correlated with lymph node metastasis ( = 0.68), stage ( = 0.72), and grade ( = 0.56), whereas E-cadherin showed negative correlations ( = −0.60, −0.59, and −0.52, respectively). ROC analysis showed areas under the curve of 0.88 zinc finger E-box-binding homeobox 1 and 0.82 (E-cadherin), suggesting their potential as biomarkers for metastasis prediction.

The study concluded that E-cadherin and zinc finger E-box-binding homeobox 1 are key predictors of lymph node metastasis, tumor grade, and stage in PTC. Monitoring these markers could enhance clinical decision-making and patient management.

Loading

جارٍ تحميل قياسات المقالة...

/content/journals/10.5339/qmj.2025.45
٢٠٢٥-٠٦-٣٠
٢٠٢٥-١٢-٠٧

القياسات

Loading full text...

Full text loading...

/deliver/fulltext/qmj/2025/2/qmj.2025.45.html?itemId=/content/journals/10.5339/qmj.2025.45&mimeType=html&fmt=ahah

References

  1. Hu S, Wu X, Jiang H. Trends and projections of the global burden of thyroid cancer from 1990 to 2030. J Glob Health. 2024; 14:: 04084. https://doi.org/10.7189/jogh.14.04084
    [Google الباحث العلمي]
  2. Abdullah MI, Junit SM, Ng KL, Jayapalan JJ, Karikalan B, Hashim OH. Papillary thyroid cancer. Genetic alterations and molecular biomarker investigations. Int J Med Sci. 2019; 16:(3):450–60. https://doi.org/10.7150/ijms.29935
    [Google الباحث العلمي]
  3. Genpeng L, Jianyong L, Jiaying Y, Ke J, Zhihui L, Rixiang G, et al. Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer. Medicine. 2018; 97:(5):e9619. https://doi.org/10.1097/MD.0000000000009619
    [Google الباحث العلمي]
  4. Ekpe-Adewuyi E, Lopez-Campistrous A, Tang X, Brindley DN, McMullen TP. Platelet derived growth factor receptor alpha mediates nodal metastases in papillary thyroid cancer by driving the epithelial-mesenchymal transition. Oncotarget. 2016; 7:(50):83684–700. https://doi.org/10.18632/oncotarget.13299
    [Google الباحث العلمي]
  5. Wan G, Zhu J, Gu X, Yang Y, Liu Y, Wang Z, et al. Human schlafen 5 regulates reversible epithelial and mesenchymal transitions in breast cancer by suppression of ZEB1 transcription. Br J Cancer. 2020; 123:(4):633–43. https://doi.org/10.1038/s41416-020-0873-z
    [Google الباحث العلمي]
  6. Lopez-Campistrous A, Adewuyi EE, Williams DC, McMullen TPW. Gene expression profile of epithelial-mesenchymal transition mediators in papillary thyroid cancer. Endocrine. 2020; 72:(2):452–61. https://doi.org/10.1007/s12020-020-02466-3
    [Google الباحث العلمي]
  7. Khalifa E. β catenin immunohistochemical expression in papillary thyroid cancer versus benign thyroid lesions in a sample of Iraqi patients. Tex J Med Sci. 2022; 6:: 1–8.
    [Google الباحث العلمي]
  8. Batistatou A, Charalabopoulos K, Nakanishi Y, Vagianos C, Hirohashi S, Agnantis NJ, et al. Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin. Endocr Pathol. 2008; 19:(3):197–202. https://doi.org/10.1007/s12022-008-9035-1
    [Google الباحث العلمي]
  9. Zhang Y, Liu G, Wu S, Jiang F, Xie J, Wang Y. Zinc finger E-box-binding homeobox 1: its clinical significance and functional role in human thyroid cancer. OncoTargets Ther. 2016; 9:: 1303–10. https://doi.org/10.2147/OTT.S96723
    [Google الباحث العلمي]
  10. Hsu Y, Liu C, Yang P, Tsai CH, Lee JJ, Cheng SP. Interaction of age at diagnosis with transcriptional profiling in papillary thyroid cancer. World J Surg. 2016; 40:(12):2922–9. https://doi.org/10.1007/s00268-016-3625-8
    [Google الباحث العلمي]
  11. Wirries A, Breyer S, Quint K. Protein kinase C inhibitor treatment attenuates hepatic ischemia and reperfusion injury in diabetic rats. Exp Ther Med. 2016; 12:(1):369–75.
    [Google الباحث العلمي]
  12. Liu Y, Wang Y, Zhao K, Li D, Chen Z, Jiang, R, et al. Lymph node metastasis in young and middle-aged papillary thyroid carcinoma patients: a SEER-based cohort study. BMC Cancer. 2020; 20:(1):1–12. https://doi.org/10.1186/s12885-020-6675-0
    [Google الباحث العلمي]
  13. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, et al. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab. 2012; 97:(6):878–87. https://doi.org/10.1210/jc.2011-2864
    [Google الباحث العلمي]
  14. Naito A, Iwase H, Kuzushima T, Nakamura T, Kobayashi S. Clinical significance of E-cadherin expression in thyroid neoplasms. J Surg Oncol. 2001; 76:(3):176–80. https://doi.org/10.1002/jso.1031
    [Google الباحث العلمي]
  15. Ivanova K, Ananiev J, Aleksandrova E, Ignatova MM, Gulubova M. Expression of E-cadherin/beta-catenin in epithelial carcinomas of the thyroid gland. J Clin Pathol. 2017; 5:(2):155–9. https://doi.org/10.3889/oamjms.2017.043
    [Google الباحث العلمي]
  16. Gao H, Sun X, Wang H, Zheng Y. Long noncoding RNA SNHG22 increases ZEB1 expression via competitive binding with microRNA-429 to promote the malignant development of papillary thyroid cancer. Cell Cycle. 2020; 19:(10):1186–99. https://doi.org/10.1080/15384101.2020.1749466
    [Google الباحث العلمي]
  17. Liu Z, Sun B, Qi L, Li H, Gao J, Leng X. Vascular mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition. Cancer Sci. 2012; 103:(4):813–20.
    [Google الباحث العلمي]
  18. Brabant G, Hoang-Vu C, Cetin Y, Dralle H, Scheumann G, Mölne J, et al. E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res. 1993; 53:(20):4987–93.
    [Google الباحث العلمي]
  19. Kapran Y, Ozbey N, Molvalilar S, Sencer E, Dizdaroğlu F, Ozarmağan S. Immunohistochemical detection of E-cadherin, α- and β-catenins in papillary thyroid carcinoma. J Endocrinol Invest. 2002; 25:(7):578–85.
    [Google الباحث العلمي]
  20. Erdem H, Gündogdu C, Sare Ş. Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma. Exp Mol Pathol. 2011; 90:: 312–7.
    [Google الباحث العلمي]
  21. Radulović P, Krušlin B. Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC). Pathol Res Pract. 2018; 1:: 246–51. https://doi.org/10.17305/bjbms.2018.2378
    [Google الباحث العلمي]
  22. Chen Z, Li S, Huang K, Zhang Q, Wang J, Li X, et al. The nuclear protein expression levels of SNAI1 and ZEB1 are involved in the progression and lymph node metastasis of cervical cancer via the epithelial-mesenchymal transition. Human Pathol. 2013; 44:(10):2097–105. https://doi.org/10.1016/j.humpath.2013.04.001
    [Google الباحث العلمي]
  23. Lee H. Expression of miRNAs and ZEB1 and ZEB2 correlates with histopathological grade in papillary urothelial tumors of the urinary bladder. Virchows Archiv. 2014; 464:(2):213–20. https://doi.org/10.1007/s00428-013-1518-x
    [Google الباحث العلمي]
  24. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009; 11:(12):1487–95. https://doi.org/10.1038/ncb1998
    [Google الباحث العلمي]
  25. Scheumman GF, Hoang-Vu C, Cetin Y, Gimm O, Behrends J, von Wasielewski R, et al. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J Clin Endocrinol Metab. 1995; 80:(7):2168–72. https://doi.org/10.1210/jcem.80.7.7608273
    [Google الباحث العلمي]
  26. Walgenbach S, Sternheim E, Bittinger F, Görges R, Andreas J, Junginger T. Prognostic value of E-cadherin in papillary thyroid carcinoma. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizin. 1998; 69:(2):186–90. https://doi.org/10.1007/s001040050394
    [Google الباحث العلمي]
/content/journals/10.5339/qmj.2025.45
Loading
/content/journals/10.5339/qmj.2025.45
Loading

جارٍ تحميل البيانات والوسائط...

  • نوع المستند: Research Article
الموضوعات الرئيسية E-cadherinepithelial-mesenchymal transitionlymph node metastasesPapillary thyroid carcinoma and zinc finger E-box-binding homeobox 1

الأكثر اقتباسًا لهذا الشهر Most Cited RSS feed

هذه الخانة مطلوبة
يُرجى إدخال عنوان بريد إلكتروني صالح
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error